Evidence map›Paper›PMID 41454997›Full record

ArticleCancer causes & control : CCC2025

Higher chemical complementarity of EBV epitopes and IGH CDR3s correlates with better outcomes for lymphoma and ovarian cancer.

Madeline C Baker, Nandini Goel, Rahul Jain, Taha I Huda, Andrea Chobrutskiy, Boris I Chobrutskiy, Joanna J Song, Veda Naga Priya Vangala, Utsav Kapoor, George Blanck

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Madeline C BakerDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Nandini GoelDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Rahul JainDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Taha I HudaDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Andrea ChobrutskiyDepartment of Pediatrics, Oregon Health and Science University Hospital, Portland, OR, 97239, USA.
Boris I ChobrutskiyDepartment of Internal Medicine, Oregon Health and Science University Hospital, Portland, OR, 97239, USA.
Joanna J SongDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Veda Naga Priya VangalaDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
Utsav KapoorDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA.
George BlanckDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, 33612, USA. gblanck@usf.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the relationship between Epstein-Barr virus (EBV) epitopes and tumor-resident immunoglobulin heavy chain (IGH) CDR3 amino acid (AA) sequences sourced from cancers with a link to EBV. In the case of ovarian cancer, the results revealed that higher chemical complementarity between certain EBV epitopes and IGH CDR3 AA sequences was linked to better outcomes. Additionally, IGH CDR3 and EBV epitope chemical complementarity was examined for Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). For both BL and DLBCL, higher chemical complementarity to certain EBV epitopes was associated with improved overall survival probabilities. This latter result may be relevant to the occasional misdiagnosis of lymphoma for ovarian epithelial carcinoma. In sum, the results justify a more detailed study of the role of EBV and the anti-EBV immune response in the ovarian cancer and lymphoma settings.

Indexed as

Complementarity Determining RegionsEpitopesEpstein-Barr Virus InfectionsHerpesvirus 4, HumanImmunoglobulin Heavy ChainsLymphomaOvarian NeoplasmsBurkitt LymphomaFemaleHumansMiddle AgedPrognosisComplementarity Determining RegionsEpitopesImmunoglobulin Heavy ChainsComplementarity-determining regionsHerpesvirus 4HumanImmunoglobulin heavy chainsLymphomaOvarian neoplasmsSurvival

Identifiers

PMID41454997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.